相关实验视频

Updated: Jun 15, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

优化的CRISPR-Cas12a全基因组屏幕揭示了胎儿血红蛋白沉默中的PTPA酸酶通路

Elizabeth A Traxler¹, Quynn Hotan², Yue Shao³

¹University of Pennsylvania Perelman School of Medicine, United States.

|January 12, 2026

概括

这项研究使用CRISPR查来识别胎儿全球蛋白 (HBG1/2) 基因表达的新调节者. 发现PTPA通过调节BCL11A来静止胎儿全球蛋白,为血红蛋白病提供了潜在的治疗标.

科学领域:

遗传学是一个遗传学.
分子生物学分子生物学
血液学血液学血液学

背景情况:

重新激活胎儿球蛋白基因 (HBG1/2) 是对血红蛋白病的治疗策略.
胎儿全球蛋白的主要抑制剂包括BCL11A,LRF3和NFIA/X.
之前对HBG1/2调节器的幕规模有限.

研究的目的:

为了对HBG1/2表达的调节者进行全面的全基因组选.
为了确定参与胎儿全球蛋白沉默的新途径.
为了发现治疗血红蛋白病变的目标.

主要方法:

一种使用CRISPR-Cas12a和CRISPR-Cas9.9的双层CRISPR选方法.
查询所有已知的人类编码基因对HBG1/2调节和红色素细胞适应性的影响.
现型救援实验以验证发现.

主要成果:

确定PTPA作为HBG1/2表达的新型消声器.
失去PTPA会增加HBG1/2水平,同时保持红状腺分化.
主要通过调节BCL11A表达,PTPA使HBG1/2沉默.

结论:

这项研究提供了迄今为止对HBG调节的最全面的CRISPR剖析.
PTPA是通过BCL11A抑制胎儿全球蛋白的关键调节者.
基因组规模的CRISPR-Cas12a查对于发现与疾病相关的途径具有强大作用.

更多相关视频

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

Introducing Point Mutations into Human Pluripotent Stem Cells Using Seamless Genome Editing

Introducing Point Mutations into Human Pluripotent Stem Cells Using Seamless Genome Editing

Published on: May 10, 2020

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...